Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Read more about Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Read more about Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma.
Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Read more about Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways.
A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Read more about A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Read more about A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Read more about A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Read more about Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients.
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Read more about HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Read more about Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
